Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis.

Abstract

The efficacy of erythropoietin (EPO) in 11 children on hemodialysis (HD) and 8 on continuous ambulatory peritoneal dialysis (CAPD) (mean age 11.8 years) was compared. The initial EPO dose was 50 U/kg s.c. once a week; the time of observation was 24 weeks. In the CAPD group, the mean hemoglobin (Hb) level increased from 7.7 +/- 0.2 to 11.2 +/- 0.6 g/dl (P < 0.001) and hematocrit (Hct) from 22.3 +/- 1.0 to 32.6 +/- 1.4% (P < 0.001), while in the HD group the mean Hb rose from 7.7 +/- 0.6 to 9.3 +/- 0.8 g/dl (P < 0.001) and mean Hct from 22.7 +/- 2.3 to 27.6 +/- 2.8% (P < 0.001) after 12 weeks of observation. An increase in Hb to over 10 g/dl was obtained in 87.5% of children on CAPD but in only 10% on HD after 8 weeks of EPO treatment. After 12 weeks of treatment, all children on CAPD had the target Hb level of more than 10 g/dl, while 7 children on HD required increased doses of EPO (100 U/kg per week). We conclude that the EPO dose of 50 u/kg given s.c. once a week is effective for children with anemia on CAPD but is insufficient for children on HD.

• Authors: M Sieniawska, M Roszkowska-Blaim
• Journal: Pediatric nephrology (Berlin, Germany) (Pediatr Nephrol) Vol. 11 Issue 5 Pg. 628-30 (Oct 1997) ISSN: 0931-041X [Print] Germany
• PMID: 9323294 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Recombinant Proteins
• Erythropoietin

Topics

• Adolescent
• Anemia (drug therapy, etiology)
• Child
• Child, Preschool
• Erythropoietin (therapeutic use)
• Female
• Hematocrit
• Humans
• Infant
• Kidney Failure, Chronic (complications, therapy)
• Male
• Peritoneal Dialysis, Continuous Ambulatory (adverse effects)
• Recombinant Proteins
• Renal Dialysis (adverse effects)